News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, ...

Singapore biotech firm Mirxes began trading in Hong Kong on May 23 at a valuation exceeding US$1 billion. Read more at ...

Linklaters has advised on Sinopec Group’s HK$7.75B exchangeable bond issuance, one of the largest by a Chinese issuer in ...

Theodore Shou, CEO of Yiyi Capital, discusses the recent strong performance of the IPO market in Hong Kong and says that the valuation premium between mainland China and Hong Kong stocks would narrow ...

H-shares as a whole still trade at a discount of 32% to A-shares, compared with a low of 28% in March, according to the Hang ...

Shanghai Futures Exchange (SHFE) and its subsidiary Shanghai International Energy Exchange (INE) have become the first ...

Shares of Jiangsu Hengrui Pharmaceuticals soared Friday morning, as more companies seek to tap Hong Kong’s capital markets.

Shares of Chinese companies Jiangsu Hengrui Pharmaceuticals and Mirxes Holdings rose sharply on Friday in Hong Kong trading debuts after raising a combined $1.4 billion in separate listings.